Ladies and gentlemen, thank you for standing by and welcome to the Elevance Health First Quarter Earnings Conference Call. At this time, all participants are in a listen-only mode. Later, we will conduct a question-and-answer session where participants are encouraged to present a single question. [Operator Instructions] As a reminder, today's conference is being recorded. I would now like to turn the conference over to the company's management. Please go ahead.

Good morning, and welcome to Elevance Health's first quarter 2024 earnings call. This is Steve Tanal, Vice President of Investor Relations. And with us this morning on the earnings call are Gail Boudreaux, President and CEO; Mark Kaye, our CFO; Peter Haytaian, President of Carelon; Morgan Kendrick, President of our Commercial Health Benefits Business; and Felicia Norwood, President of our Government Health Benefits Business. Gail will begin the call with a brief discussion of the quarter, recent progress against our strategic initiatives, and our updated outlook for the year. Mark will then discuss our financial results and outlook in greater detail. After our prepared remarks, the team will be available for Q&A. During the call, we will reference certain non-GAAP measures. Reconciliations of these non-GAAP measures to the most directly comparable GAAP measures are available on our website, elevancehealth.com. We will also be making some forward-looking statements on this call. Listeners are cautioned that these statements are subject to certain risks and uncertainties, many of which are difficult to predict and generally beyond the control of Elevance Health. These risks and uncertainties can cause actual results to differ materially from our current expectations. We advise listeners to carefully review the risk factors discussed in today's press release and in our quarterly filings with the SEC. I will now turn the call over to Gail.

Thank you, Steve, and good morning, everyone. We appreciate you joining today's earnings call. I'm pleased to report that Elevance Health delivered first quarter GAAP earnings per share of $9.59 and adjusted diluted earnings per share of $10.64, reflecting growth of 12.5%. These results reflect disciplined execution of our strategic initiatives during a dynamic time for our industry. Given the solid start to the year, we have increased our guidance for adjusted earnings per share by $0.10 to be greater than $37.20. We are making significant progress on our enterprise strategy in 2024 to accelerate capabilities and services, invest in high growth opportunities, and optimize our Health Benefits business. On Monday, we announced the next step in our journey to expand access to high-quality patient-centered value-based care in our local markets. After years of experience working closely with care providers to advance value-based care, we are confident that our hyper-local approach, which aligns the right incentives, real-time patient information and clinical decision support tools, delivers better health outcomes, improved consumer and provider experience, and greater affordability. Accordingly, we entered into an agreement to form a strategic partnership with Clayton, Dubilier & Rice to build a payer-agnostic advanced primary care and physician-enablement business, serving consumers across commercial, Medicare, and Medicaid health plans, consistent with the diversity of our own medical membership. Upon formation, the combined company will serve nearly 1 million consumers. The new venture will bring together the strengths of three innovative care provider entities, including certain care delivery and enablement assets of Carelon Health. Importantly, we have worked closely with these companies and their management teams and are confident in the value they deliver for our Medicare, Medicaid, and commercial health plan members and employers. We're excited to collaborate with CD&R and a broad range of care provider partners…

Thank you, Gail. As you heard earlier, our first quarter results reflect solid performance under a dynamic operating environment. We ended March with 46.2 million members reflecting Medicaid attrition, partially offset by ongoing momentum in our commercial business. During the quarter, we added nearly 400,000 commercial fee-based members, driven by strong retention and a successful national account selling season, and over 200,000 individual ACA members, given our attractive product positioning and coverage transitions away from Medicaid. Medicare Advantage membership declined slightly, as expected, given select market exits and the collective actions we continue to take to establish a strong foundation for profitable and sustainable growth over the long term. Operating revenue for the quarter was $42.3 billion, in line with our expectations. The consolidated benefit expense ratio of 85.6% improved 20 basis points year-over-year due to disciplined premium rate adjustments to reflect medical cost trends and the ongoing recovery of commercial margins from pandemic era lows. The adjusted operating expense ratio was 11.4%, consistent with the first quarter of 2023, indicative of our commitment to disciplined expense management and investment prioritization. Solid performance and growth in operating gain for both our health benefits and Carelon segments of $138 million and $72 million respectively, led to growth in consolidated adjusted operating gains of over 7%. Carelon Services had a particularly strong start to the year with revenue and operating earnings growth driven by risk based service line expansions and effective cost management, especially in our Carelon Insights and Carelon Behavioral Health businesses, further accelerating our enterprise flywheel or growth. Operating cash flow in the first quarter was $2 billion, or approximately 0.9 times net income. With respect to the balance sheet, we ended the quarter with a debt to capital ratio of 39.4%, in line with our target range, preserving ongoing…

[Operator Instructions] For our first question, we'll go to the line of Lance Wilkes from Bernstein. Please go ahead.

Great. Thanks so much. Let me ask a little bit about the value-based care strategy and the execution that's obviously a really big step forward. Could you talk a little bit about kind of the vision and scope of this? Is this going to be more focused on enablement or in particular markets, is practice ownership going to be important? Then maybe if you can kind of color in the picture a little bit as far as leadership, names, which Carelon assets are going to be contributed. And near term, do you see which areas of leverage across the membership base of Elevance, do you see this being able to penetrate most effectively? Thanks.

Well, great. Thanks so much for the question, Lance. First, as I shared on in my opening comments, we're very excited about this partnership with CD&R, because it is very much the next step in our journey to bring value-based care to more consumers, specifically about partnering closely with care providers. And we see it as absolutely consistent to driving greater risk adoption and advancing our specialty enablement strategy as well. So it's very much a first step there. And as you said in your question, this aligns very closely with our strategy and our broad partnership focus to work directly with care providers in our local markets. And our goal again remains to increase more downside risk sharing in our value-based arrangements. I think, to take a step back, what makes this approach unique is that we're enabling value-based care across all lines of business. So, as I shared, the combined company is going to be payor-agnostic, and it's focused on enabling advanced primary care locally. And from the get-go, it's going to serve nearly 1 million consumers, and that's going to be across our commercial, Medicare and Medicaid health plans upon formation. Another thing I think is important is that it provides the opportunity to pull through Carelon services to support those patients and accelerate that specialty enablement for complex and chronic patients. We have been working with these management teams and these assets for some time and feel very confident about the alignment of our goals to serve as a lifetime trusted health partner. The goal gets back again to focusing on whole health, the needs of consumers, driving greater affordability, and fundamentally differentiate a consumer experience. A few things about the partnership too, and again, what makes it different for patients. They're going to have access to integrated teams. We're looking at personalized navigation, expanded digital assets, and specialized services. The primary care model is going to be built to be very distinctive, including community practices, purpose-built clinics, high-risk clinics, and digitally-enabled care models. So, as you can see, it's a fairly comprehensive approach. And the last thing I'd say is that employers in the market have not historically had access to a lot of these capabilities. And we have seen through the work that we're already doing, that this dedicated primary care capacity that integrates the clinical and benefits navigation with their specific health and wellness strategies is truly differentiating. So again, this is being purpose-built to work across all of the aspects of [Medicare, Medicare] (ph), commercial, not just a single business. So very much excited. We see this as an opportunity to accelerate innovation in the space and improve healthcare outcomes and consumer experiences. So thanks very much for the question. Next question, please.

Next, we'll go to the line of AJ Rice from UBS. Please go ahead.

Hi, everybody. Thanks for the question. I appreciate Mark's comments about the buildup, a little bit in days in claims payable, but just maybe to flesh out a little bit more the impact of the Change cyber-attack on results. Do you have a census of what percentage of your claims that you normally see in the first quarter may still be out there? Do you feel like you've got a good handle on that? And anything when you address that in terms of your normal IV&R, maybe you've got a significantly higher level of IV&R because you're allowing for the Change and if you can break out what you're actually seeing a little bit on cost trends versus needing to sort of provision for the unknowns of the Change cyber-attack.

Thanks for the question, AJ. Let me maybe provide some broad-based comments and then I'll turn it over to Mark to provide a little more specificity on your questions. Now, I want to say first and foremost, I'm really proud of our teams and how they responded to this issue that occurred with Change quickly and effectively, first to protect our members and their data, and also help our care providers maintain their operations and cash flow. Importantly, I think it's important to note that from a perspective, we were not as significantly impacted by this and we are back to normal operations in terms of claims flow. Importantly, another thing that's really important to understand is our prior authorization provider payments and pharmacy claims were not materially impacted as well because they don't go through Change. We don't use Change significantly for those. So with that, I'll turn it over to Mark to provide a little more comments. But I think framing it overall, we feel that our teams acted quite quickly and really proud of our ability to work in the ecosystem to help support them.

AJ, as you just heard from Gail, we acted quite responsibly to sever our network connections to Change Healthcare and to protect the data of both our members and providers. While we initially observed a 15% to 20% reduction in the daily volume of electronic data receipts from providers, most of which were claims related, in recent weeks our extensive efforts have led to a significant catch-up in outstanding claim volumes. And for the quarter, we are effectively caught up on claims receipts and are now working to complete all necessary claims adjudication and processing activities. As such, as part of the normal reserving practices, we've reflected the appropriate impact of the industry-wide disruption related to Change Healthcare in the reserves we've reported for our first quarter financials, and that ensures both consistency with historical practice and prudence. And then to your specific question, the impact here was to increase our sequential days in claims payable quarterly result by approximately 1.7 days.

Thank you. Next question, please.

Next, we'll go to the line of Josh Raskin from Nephron Research. Please, go ahead.

Hi, thanks. Good morning. I wanted to get back to the partnership with CD&R and specifically what alternatives did you evaluate and consider before coming to this arrangement? And I think in the past, you were stressing more and I've heard it today as well that focus on specialty care. So how does that fit in and sort of get bolted on, on top of this? And maybe where does this fit into your longer term national approach? And then how important was it that you could serve multiple memberships inside not just Medicare Advantage? Thanks.

Yeah, thanks for the question, Josh, because I think it very much aligns to the strategy that we've laid out. I guess first and foremost, it's payor-agnostic, and it was really important. We've always said that our goal, given the diversity of our business mix, serve all members across all business lines, given the depth and density of our membership on our local markets, that is very important. We had a partnership already working with many of these assets. So as I said, we know the membership -- we know the leadership teams, we know the value that can be created. And so, we have been working with them and feel quite good about what we can create. This is payor-agnostic, which we also think is very important. And again, this will help us continue through having a focus on advanced primary care, it's still very much focused on our chronic patients and complex patients. And we are still building specialty care enablement, which is, again, another very important component of what we're trying to probe through. So I think from that value-based care across all lines of business, a critical part of our strategy, very consistent, driving value-based care, continuing to drive much more downside risk, which means that we needed strong enabling capabilities to help practices work their way through that. We know that it takes time. It is also a technology-driven model. So one of the nice things about this partnership is that there are embedded technology assets to digitally-enabled care as well. And then we have a focus on patient access and experience in the adoption of next generation models. So again, consistent with the strategy that we've had over the last several years, not really a diversion, I think, from that. And I think the timing for us was right because we have been experimenting with multiple models and have a lot of experience in the space right now. So thank you very much for the question. Next question, please.

Next, we'll go to the line of Ben Hendrix from RBC Capital Markets. Please go ahead.

Hey, thank you very much. Just another question on the CD&R partnership. To what extent are these primary care platforms taking risk currently? Is that something that we will need to see develop as we kind of get more of these digital enablement abilities from Carelon? Just wanted to see if over the five-year horizon to full ownership, if we can expect to kind of get the full capitation on those platforms over that time period? Thanks.

Thanks, Ben. I'm going to have Pete probably provide a lot more context. But just quickly, about a third of the membership is under risk arrangement now. So with that, Pete, why don't you give a little more color into the relationship and how we see it evolve.

That's great. Thanks for the question, Ben. And I'll give you a little bit more color on the assets and the capabilities. They really all have their distinct strengths. We see great opportunities, quite frankly, to cross-pollinate. When you think about MPG to your question on risk, they really are a leader in managing Medicare and commercial risk. And they've also got a very strong chassis I think, for future growth and a proven model in that regard in terms of acquiring and providing practices. So very strong at managing risk and a lot of capabilities in that regard. What's really interesting about apree and Gail referenced this is they've got a differentiating technology and navigation capabilities with a real strong focus on the commercial business. So a really nice entry point for us. We've been working on relationships already in this regard. And I'm really excited about that because we, obviously, as a company, have a really strong commercial footprint, a really nice entry point for us. And then, of course, Carelon Health advanced primary care which is a leader in managing the complex and the chronic and largely takes risk today. We see a tremendous opportunity in a variety of ways for that. One, from a technology perspective, state-of-the-art EMR that we can upgrade as well as from a growth perspective in terms of partnering with MPG and apree. And then finally, and Gail mentioned this, but I'll reiterate it, a tremendous opportunity to wrap around existing Carelon services to this arrangement that will create value for all three assets. So, appreciate the question.

And then 1 quick financial remark just at the end of Pete's comments there. We do expect the consolidated entity once formed to have over $4 billion in annualized debt revenue.

Thank you. Next question, please.

Next, we'll go to the line of Dave Windley from Jefferies. Please go ahead.

Hi. Good morning. Thanks for taking my questions. I'll switch topics over to Medicaid. Your redetermination enrollment impacts seem to, maybe pick up some momentum in the quarter. I think you said 90% of members have now been redetermined. I wondered If you could give us some view of kind of how you expect that to gate out over the next several quarters? And then from a risk pool and rate adequacy standpoint, could you update on how that looks now that the membership is whittling down? Thank you.

Thank you. I'm going to have Felicia Norwood address your questions.

Good morning, Dave, and thank you for the question. Frankly, right now we're at a point where our Medicaid business is actually tracking very much in line with our expectations. As you referenced, we believe that about 90% of our members have had their eligibility redetermined. So as we go through the next few months, you certainly see this tapering down as we really wrap up the unwinding process as we get through June. One of the things I want to make sure you understand, the downward trend in membership in the first quarter resulted not just from re-determinations, but footprint changes as well. So it's really the cumulative impact of those two things in terms of the first quarter. When we think about the work that we will continue to do is we will continue to outreach to Medicaid members. Many members who have lost their membership at this point did that as a result of really procedural reasons. So the team will continue to be very aggressive around continuing the outreach that's been going on. And we're really proud of the work that we continue to do to really reach out to over 4.5 million people, as Gail referenced in the opening comments, to make sure that individuals who are truly eligible for Medicaid have access to Medicaid and, if not, are able to transition to an exchange product and continue coverage. In terms of where we are today with respect to, the acuity and mix of that membership, the acuity is in line with what we expected. And I will also say that at this point we have visibility into 75% of our Medicaid rates and premiums for 2024. The vast majority of those are in line with our expectations and they're actuarially sound. As you know, we have ongoing conversations with our state partners as we go throughout this process and we expect those rates to continue to be actuarially sound. So we're going to continue to work with our state partners. We're going to continue the advocacy with our members in terms of making sure they have access to care and coverage. And we're going to make sure that we go through this process with a lot of discipline and rigor, understand the mix of our membership and the levers versus [payors] (ph) as we go through this process. Thank you for the question.

Next question, please.

Next, we'll go to the line of Lisa Gill from JPMorgan. Please go ahead.

Hi, good morning and thank you. I was wondering if maybe you could talk about utilization trends by line of business and what you saw in the quarter versus your expectation.

Lisa, thanks very much for the question. So utilization in the first quarter in our health benefits businesses was in line with our expectation and that was reflected in our reported benefit expense ratio of approximately 85.6%. In the commercial business, specifically inpatient and outpatient authorization levels year to date were aligned with our expectations and our internal year-to-go trend remains unchanged. On Medicare, as expected, we saw utilization related to both the two midnight rule for inpatient stays as well as pockets of outpatient authorizations around, for example, at radiology and cardiovascular procedures. And importantly, these trends were broadly planned for as part of our underlying cost trend assumptions. Medicaid, as you heard Felicia talk about a moment ago, did experience increased but state-specific utilization attributed to the redetermination, mix impacts, and we remain very comfortable with what we're seeing there given those ongoing constructive dialogues with the impacted states. And so overall, we remain confident that both our MA bids for 2024 and our commercial pricing really reflect the appropriate projections for utilization and medical cost trends.

Next question, please.

Next, we'll go to the line of Kevin Fischbeck from Bank of America. Please go ahead.

Great. Thanks. Just wondering if, it's not a huge increase in guidance, but would love to kind of hear what was driving the increase in guidance. Is it something on the health plan side? Is it on the Carelon side? And I guess just thoughts about how you thought about providing increases in guidance. It sounds like you believe that visibility is relatively high in claims, but obviously there's some concern there. So I don't know if there's any conservatism or thought about pace of raises versus what you're actually seeing in the core business today. Thanks.

We were pleased to report our adjusted deleted EPS this quarter, which came in slightly better than our seasonal expectation. And that was led by solid performance in both our health benefits and Carelon divisions, where operating margin increased by 30 basis points and 20 basis points respectively, highlighting what we see as disciplined execution of our initiatives during a dynamic time for the industry. Of specific notes, and you referenced this in your question, was the favorable performance in the first quarter benefit expense ratio and that was driven by commercial margins that continue to recover from pandemic era lows. We're very pleased with the Q1 results. It's still early in the year and given our business is subject to some variability around medical cost trends, we're intentionally remaining thoughtful and prudent in our outlook and that led us to increase our guide for adjusted EPS by $0.10 to be greater than $37.20.

Next question, please.

Next, we'll go to the line of Whit Mayo from Leerink Partners. Please go ahead.

Hey, thanks. Just wanted to hear any comments on the external revenue growth with Carelon Services. Did that grow faster than the overall segment? You did, I think, reference some strong external growth. So curious what might be gaining traction in the market. And then just a quick question on guidance. Mark, you've averaged maybe 55% to 56% of earnings in the first half. Any reason that would be different this year? Thanks.

Great. Why don't I have Pete address sort of the Carelon questions and then Mark will talk about the earnings percentages. Pete?

Yeah, thanks for the question. As it relates to Carelon external growth, we continue to see a really nice momentum in our build. I mean, for 2024, from an overall sales perspective, we've already this time of the year, exceeded what we did in all 2023. And you heard Gail mention in her prepared remarks several new wins, which we're really excited about, really growth across the portfolio with some notable wins in behavioral health. She mentioned winning a statewide account in Medicaid for Maryland, which we're really excited about, and then some new innovative solutions with large employers as well as wins in the state of California. And on the behavioral health side, also some select wins in the crisis space, so areas that we've been really focused on. In addition to that, we've had some notable wins with the Blues related to our insights business. We've talked about this before, but it's really critical that we prove some of our risk arrangements and our differentiated capabilities in Elevance and then port those to the Blues. And we've seen that play through with several notable wins. Lastly, I'd say we're excited about the ‘25 pipeline. We're obviously actively in the selling season, our pipeline is very rich. And again, I would say a large focus on our insights businesses, as well as our behavioral health businesses.

On your second question, the seasonality of the adjusted diluted EPS in 2024 is expected to be consistent with the past several years with approximately 55% of earnings in the first half of the year. I also want to call out that workday seasonality, given it is a leap year, did result in a smaller than historically normal impact in the first quarter. But we expect the workday seasonality to put slightly more pressure on the third quarter MLR with an offsetting favorability than in the fourth quarter as those workdays normalize.

Thanks, Mark, and thanks for the question, Whit. And I just want to add to Pete's comments about just the momentum that we're seeing inside of Carelon. First, our proof points are within Elevance Health, and then secondarily now seeing some really nice momentum and traction externally. So thanks for the question. And next question, please.

Next, we'll go to the line of Nathan Rich from Goldman Sachs. Please go ahead.

Great. Good morning, and thanks for the questions. Gail, I wanted to follow up on your comments on the Medicare business and the goal of balancing growth and margins. Could you maybe just elaborate on that, given the tougher rate environment that you highlighted? And I think the companies prioritize margin improvement in Medicare this year. Does that kind of remain on track for 2024? And do you expect to plan for further improvement in 2025?

Thanks for the question, Nathan. As I shared in my opening comments, first of all, the Medicare rate announcement, as you've heard, represents the second year of consecutive cuts to the program that we know will result in increased premiums and reduced benefits for seniors with disabilities and particularly those that have really needed this program. Our approach is very consistent. We're going to continue to be disciplined in our approach to the Medicare business. Our focus is to get consistency, high-value competitive benefits, and balanced growth and margins. We're focused on building a sustainable, attractive, long-term business. It's too early to provide specifics for the 2025 bid at this stage, but again, I'm going to repeat, we're looking to really balance growth and margins. As we talked about in our Investor Day, our focus is on keeping our members Blue for life and there we’re focused on particularly our 14 Blue states and continuing to prioritize the very significant business we have in DSNP where our unique competitive advantage is serving the needs of those consumers with complex conditions. So overall, we're in the midst of the process right now, so we'll have more as we get through the bid process, but thank you very much for the question. Next question, please.

Next, we'll go to the line of Stephen Baxter from Wells Fargo. Please go ahead.

Hi, thanks. Just interested. It seems like now you're talking about an at least 12% EPS CAGR as your long-term expectations in both the slides and the prepared remarks. Like obviously in the past, you've talked about a 12% to 15% EPS growth CAGR target. Just wondering what if anything, we should be reading into that? Thank you.

Thank you very much for the question. You should see these two targets as synergistic. We remain firmly committed to achieving a long-term adjusted earnings per share CAGR of 12% to 15% through 2027 as we communicated at our Investor Day event last year. And then as we think more broadly around the long-term, we have confidence that through business cycles and over time, the earnings power of our health benefits and Carelon flywheel will generate the momentum and the foundation that's needed to sustain a long-term compound annual growth rate of at least 12%.

Next question, please.

Next, we'll go to the line of Sarah James from Cancer Fitzgerald. Please go ahead. And Sarah, your line is open.

Next, we'll go to the line of Andrew Mok from Barclays. Please go ahead.

Hi. Good morning. Hoping you can give us an update on your transition of specialty scripts to BioPlus and help us understand the contribution that that's expected to have this year. Thanks.

Thanks. Let me have Pete address your question.

Yeah, thanks for the question, Andrew. Listen, the integration of BioPlus is going well. As you know, we remain on an accelerated calendar regarding this. I'll just reiterate, we spent last year building out the infrastructure and the team, and we did begin migrating scripts in January of this year. And we're doing so really on a staged basis. So we'll continue to do the migration throughout ‘24 and into 2025 as it relates to the Elevance Health book of business. I'd say overall things are going well. The infrastructure build is going well in addition to the BioPlus dispensing facilities that are in place. We're live with one additional facility now as we speak and we have two more going live this year. So we feel very good about the capacity, not only with respect to the Elevance Health business, but business beyond that. So we're excited, we're on a path, and again it will be staged throughout ‘24 and ‘25.

Yeah, in addition, I'll just add to what Pete said, to BioPlus, as you know, we also announced the acquisition of Kroger Specialty Pharmacy, and that is also well aligned to Carelon’s effort to control those levers that matter. So thank you for the question. Next question, please.

Next, we'll go to the line of George Hill from Deutsche Bank. Please go ahead.

Hey, good morning, guys, and thanks for taking the question. I -- Gail, first I'd like to follow up on Dave's question on Medicaid and I guess can you talk about where you think we are in the kind of where, in -- I guess, in the calendar and the mix of rate determinations versus acuity mix and kind of I guess I'm trying to get a sense for how far behind do you think the kind of the rate repricings are versus the changes in acuity mix from redetermination? And given that you just talked about specialty, I'd love if you could just add a comment on the Kroger deal and if you expect those scripts to transfer over to BioPlus and how you think about the stickiness of those scripts?

Yeah, George, I think Felicia pretty much covered your question, which is, we think things are quite aligned at this point. So in terms of the acuity and the mix, everything, we have visibility into 75% of our Medicaid premiums. We've had very constructive discussions with our states. So, overall, we feel things are lining up. They're actuarially sound, and our conversations are ongoing. So, I feel very good about our Medicaid business, just to sort of put a finer point on that. In terms of Kroger, I'm going to ask Pete to comment on Kroger and how that's going to align with our broader pharmacy business.

Yeah, George, thanks for the question on Kroger. And as Gail alluded to it, we're excited about this deal. It furthers the Carelon and the pharmacy strategy. It certainly is a natural extension of our recent arrangement with BioPlus. And just to give you some background, Kroger Specialty Pharmacy is the largest non-payer-owned specialty pharmacy. They do about 500,000 scripts a year, And it really is a natural complement to what we're doing with both BioPlus and Paragon, quite frankly. To give you a sense of what this is going to do for us, it's going to add meaningful scale. It increases our access to more LDDs, limited distribution drugs, which is very important. Certainly strengthens our relationship with manufacturers, enabling us to really provide greater affordability and quality. And in fact, it has a nice presence in Puerto Rico, which could be very helpful to our MMM business. As it relates to your question on transition of scripts, we feel very good about that. I mean, obviously, in this case with specialty pharmacy, providers and members have choice, but we feel very good about the execution model. We feel very good about the stickiness of the scripts, and we believe the integration and the transition will be straightforward. We expect the arrangement to likely close in Q3 and Q4 this year.

Next question, please.

Next, we'll go to the line up Scott Fidel from Stephens. Please go ahead.

Hi, thanks. Just interested if we could double-click on the Carelon Services margins in the first quarter with the 90 basis points of expansion. Anything specifically that you would call out there, and then that pacing does seem to be quite a bit stronger than the full-year guidance where you had sort of called for a flattish to down 30 basis points. So, curious whether you have any updates for us just on how you expect Carelon Services margins to trend for the full year. Thanks.

Thank you very much for the question. Margins were better than expected in the first quarter, and that aligned very well to very strong revenue growth in the quarter, given the launch of several new internal risk deals, which we expect to accelerate as the year goes on. We're not seeking to update our full year guidance at this time, given that both the seasonality of the business continues to evolve as we expand our risk-based revenue and the timing of new product launches is anticipated to result in some transitory quarterly volatility. But let me turn it over to Pete for a couple of minutes to talk about what we're doing.

Yeah, no, it's appreciated. And Mark's really covered it. But think about it this way. We are launching some pretty significant risk arrangements this year. We've talked about it, but a full risk arrangement in oncology, a full risk arrangement with the seriously mentally ill. And you should think about this as a natural cadence to launching this throughout the year, and that's what's going to impact the margins. So, for example, with the seriously mentally ill, we're doing this largely with the Medicaid business. It's not a big bang across all the Medicaid states immediately, as you'd expect. It's more methodical state by state in ‘24 and ‘25.

Next question, please.

Next, we'll go to the line of Justin Lake from Wolfe Research. Please go ahead.

Thanks. Good morning. There are some significant changes coming in the Part D space for 2025. I was curious as to your view on what that could mean for premiums. Just maybe you could tell us where you think kind of industry premiums are this year and where how significant that increase could be for 2025.

I'm going to ask Felicia to address that.

So, good morning, Justin, and thank you for the question. There are significant changes coming for 2025, and I'll say this, it's early to provide specifics around what our 2025 strategy is going to be. But as Gail mentioned before, we are going to make sure that we have a very balanced approach as we think about the margins around our Medicare business and focus on those things that we believe bring the highest value to our members as we really work to make sure we have a competitive product in-market that meets the needs of those members that we're trying to serve with a lot of dynamic changes that are going on in the Medicare environment for 2025. So thank you for the question.

Next question, please.

Next, we'll go to the line of Ann Hynes from Mizuho. Please go ahead.

Yeah, thank you. Congrats on retaining the Florida contract, but it looks like you're actually gaining market share. Can you let us know the membership growth? And also looking ahead over the next couple of years, is there any big state renewal risks for Elevance and alternatively, is there any big RFP opportunities for you? Thanks.

So, good morning, Ann, and thank you. We are certainly very pleased with the results in Florida. It's a state that we have been partnering in for a long period of time, but certainly the win here allows us to expand our footprint and additionally serve some complex populations, particularly SMI, which will be very much kind of a collaboration with our Carelon Services business, so very excited about that. We are also very focused on our Virginia go-live, which is coming up in July as well. So a lot of work happening there. Outstanding at this point is certainly Georgia, where we will be defending our procurement with respect to our core business, as well as our foster care business in the state of Georgia, and feel very good about the work that we continue to do there in partnership with the state. In addition, we are very much focused on a couple of new geographies where we are bidding this year and look forward to hearing those results. But on top of that, the states are very much focused on specialty populations, and we see that as the opportunity for growth as we go forward. Medicaid is a very important business for us. Our recent RFP wins, I think, demonstrate the value that we bring to our state partners, but more importantly, the improvement in quality of outcomes that we are providing to Medicaid beneficiaries. So thank you very much for the question.

Next question, please.

Next, we'll go to the line of Gary Taylor from TD Cowen. Please go ahead.

Hi. Good morning. Two quick ones for me. I just wanted to come back to Medicaid for a second. I mean, it's obvious your commercial book is doing very well, but you had expected Medicaid margins to come down this year, but you're saying the rate adjustments you're getting are actuarially sound for the acuity changes. So should we think about the lower Medicaid margins this year primarily just the deleveraging the OpEx impact of losing the revenue and enrollment and that MLR is going to be fairly stable? And then just my second question was, Mark made this comment, John made this comment for years about how days claims payable would eventually come down into the low 40s. That's a lot of inherent or embedded earnings power that could come through the P&L at some point over time. Can you give us any sort of sense of what long-term means in terms of seeing the reserves move lower?

Gary, good morning and thank you for the questions. Let me start maybe with the margins and let me bring it up to the health benefits business segment to talk about first. So in terms of health benefits, the margins this quarter were very much in line with our expectations. It puts us squarely on track to achieve our guidance for the full year of an increase between 25 basis points and 50 basis points. I'm not looking necessarily to comment on a single business' margin, but you could expect Medicaid margins to normalize, given we already have line of sight, and you heard Felicia talk about this, into approximately 75% of the Medicaid premiums for 2024, and that we are comfortable with the actuarial soundness of the rates that we are seeing. Over the long term, Medicaid continues to normalize as we spoke about last quarter, and it is performing as expected. On the DCP, for 2024, if we look out through the end of the year, we're anticipating remaining in the mid to upper 40s range given Medicaid membership is expected to decline to within our guidance range of 8.8 million to 9.2 million members. And as you know, Medicaid has a slightly lower relative DCP compared to commercial, for example. And then over time, to reiterate the guidance, we do expect over the long term, DCPs to return to that more normalized range in the low 40s.

Thank you, Mark. One more question, please.

And for our final question, we'll go to the line of Sarah James from Cantor Fitzgerald. Please go ahead.

Thank you. Just wanted to clarify a couple of things. One, on the reserve boost, are you saying the 1.7 days is fully related to conservatism via Change? Because that seems like about a $600 reserve boost to us, so I wanted to see if there was any other factors in that 1.7 days. And second, could you give us a sense of your Medicaid rate seasonality? Like, what percent of your book renews in 1Q versus 2Q versus 3Q?

On your first question, the sequential increase in days in claims payable at quarter result of 1.7 days is primarily related to the Change Healthcare. I just want to -- -maybe one clarification around this. It's worth noting that neither the decrease in claims receipts that we saw during the quarter or the reserve accrual that we took related to Change Healthcare had any discernible impact on our benefit expense ratio or P&L. And that's because we believe the reserve represents an amount we would otherwise have paid had there been no disruption. So you should think about this as overall for the quarter, incurred claims are completely consistent with our expectations. Given some of the notes that came out this morning, I also would like to just reiterate that we do expect operating cash flow to be at least $8.1 billion for the full year, reiterating our earlier guidance.

And, Sarah, just on your question with respect to our Medicaid states and when our rates are up for renewal, we have roughly 10 states that renew in January, another state that renews in April, another nine that renew in July, and then the last two renew in the back half of the year in September and October.

Well, thank you very much for your questions. Just in some closing thoughts, we're very pleased to be off to a solid start this year, and we're confident, as you heard in the ongoing execution of our strategy and the balance and resilience of our diverse set of businesses positions us well for 2024 and beyond. We're very excited about the future and look forward to sharing more on our progress with you in the coming year. Thank you for your interest in Elevance Health and have a great rest of your week.

Ladies and gentlemen, a recording of this conference will be available for replay after 11:00 a.m. today through May 17, 2024. You may access the replay system at any time by dialing 800-876-4955. International participants can dial (203)-369-3997. This concludes our conference for today. Thank you for your participation and for using Verizon conferencing. You may now disconnect.